Congenital Hypoplastic Anemia Recruiting Phase 2 Trials for Rituximab (DB00073)

Also known as: Diamond-Blackfan Anemia / Fanconi's Anemia / Hypoplastic anaemia / Fanconi Anemia / Anemia, Hypoplastic / Congenital hypoplastic anemia / Anemia, Diamond-Blackfan / Hypoplastic anemia / Fanconi Anemias / Hypoplastic Anemias, Congenital / Diamond Blackfan Anemia / Anemia, Diamond Blackfan / Anemia, Hypoplastic, Congenital / Blackfan-Diamond syndrome / Congenital aplastic anaemia / Congenital aplastic anemia / Constitutional aplastic anaemia / Constitutional aplastic anemia / Anaemia hypoplastic / Anemia hypoplastic / Diamond-Blackfan anaemia / Fanconi's anaemia

IndicationStatusPhase
DBCOND0052431 (Congenital Hypoplastic Anemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03579875T Cell Receptor α/β TCD HCT in Patients With Fanconi AnemiaTreatment